A191420 Stock Overview
TegoScience Inc., a biotechnology-based cosmetics company, engages in the production and sale of skin cell therapy products from human epithelial cells in South Korea.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
TegoScience Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩21,900.00 |
52 Week High | ₩25,700.00 |
52 Week Low | ₩7,430.00 |
Beta | 1.4 |
1 Month Change | 10.61% |
3 Month Change | 86.38% |
1 Year Change | 51.35% |
3 Year Change | -16.09% |
5 Year Change | -39.67% |
Change since IPO | 41.06% |
Recent News & Updates
Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Feb 16How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?
Jan 12Shareholder Returns
A191420 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -9.5% | -5.0% | -4.3% |
1Y | 51.3% | -3.5% | -1.0% |
Return vs Industry: A191420 exceeded the KR Biotechs industry which returned -2.6% over the past year.
Return vs Market: A191420 exceeded the KR Market which returned 0.6% over the past year.
Price Volatility
A191420 volatility | |
---|---|
A191420 Average Weekly Movement | 10.1% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 12.0% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A191420's share price has been volatile over the past 3 months.
Volatility Over Time: A191420's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 51 | Saewha Jeon | www.tegoscience.com |
TegoScience Inc., a biotechnology-based cosmetics company, engages in the production and sale of skin cell therapy products from human epithelial cells in South Korea. The company’s products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services.
TegoScience Inc. Fundamentals Summary
A191420 fundamental statistics | |
---|---|
Market cap | ₩175.34b |
Earnings (TTM) | -₩2.32b |
Revenue (TTM) | ₩7.77b |
22.6x
P/S Ratio-75.5x
P/E RatioIs A191420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A191420 income statement (TTM) | |
---|---|
Revenue | ₩7.77b |
Cost of Revenue | ₩2.50b |
Gross Profit | ₩5.28b |
Other Expenses | ₩7.60b |
Earnings | -₩2.32b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -290.08 |
Gross Margin | 67.89% |
Net Profit Margin | -29.88% |
Debt/Equity Ratio | 2.9% |
How did A191420 perform over the long term?
See historical performance and comparison